PAK4 and breast carcinoma: Collectively, these findings suggested that PAK4 may be a negative regulator of ERα transactivation in ERα+ breast cancer cells, which may contribute to the progression of breast cancer by allowing the development of ERα-negative phenotypes, leading to increased aggressiveness in ERα+ breast cancer cells.